← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, esters with tertiary amino group
mebeverine
A03AA04
Forms & Strengths
- Capsule, sustained-release: 200 mg
- Tablet, coated: 135 mg
- Oral suspension: 50 mg/5 mL
Adult Dosing
- Capsules: 200 mg orally twice daily, taken 20 minutes before meals
- Tablets: 135 mg orally three times daily, taken 20 minutes before meals
Pediatric Dosing
- Not recommended for children under 10 years of age due to lack of clinical data
- Children 10 years and older: Adult dosing regimen may apply based on clinical guidance
Indications
- Symptomatic relief of irritable bowel syndrome (IBS)
- Treatment of gastrointestinal spasm secondary to organic bowel diseases
Mechanism of Action
- Direct-acting antispasmodic on the smooth muscle of the gastrointestinal tract
- Exerts a local anesthetic effect on smooth muscle cells
- Blocks voltage-gated sodium channels and inhibits phosphodiesterase activity
- Prevents depletion of intracellular stores of noradrenaline
- Normalizes gut motility without altering normal autonomic gut motility
Contraindications
- Hypersensitivity to mebeverine or any excipients in the formulation
- Paralytic ileus
Adverse Reactions
- Rash, urticaria, angioedema (rare hypersensitivity reactions)
- Dizziness
- Headache
- Nausea
- Indigestion, constipation, or diarrhea
Drug Interactions
- No formal pharmacokinetic drug-drug interaction studies have been performed in humans
- Animal studies suggest negligible potential for pharmacokinetic interactions
- No known clinically significant interactions with alcohol
Curated Content: Needs Vetting Before Put to Clinical Use